Table 5.

Survival analysis of clinico-pathological variables and MYC amplification

			95% CI
	Mean Months	Std. Error	Lower Bound	Upper Bound	p-value
Stage
1	119.59	9.62	100.73	138.45
2	92.03	7.75	76.85	107.21
3	98.25	15.12	68.61	127.89
4	18.25	6.02	6.45	30.05	p < 0.001
Size (T)
T1	89.35	4.53	80.47	98.23
T2	100.60	9.98	81.04	120.17
T3	82.50	16.74	49.69	115.32	p = 0.06
Distant Metastases
No Metastatic Disease (0)	114.88	7.06	101.05	128.71
Metastatic Disease (1)	38.78	13.97	11.40	66.16	p < 0.001
Lymph Nodes
Lymph Node Negative (0)	124.65	8.29	108.40	140.90
Lymph Node Positive (1)	86.88	10.33	66.64	107.11	p = 0.039
Breast Cancer Molecular Subtype
Luminal A	67.71	7.99	52.05	83.36
Luminal B	94.00	4.82	84.56	103.44
HER 2+	71.00	13.73	44.09	97.91
Triple Negative Breast Cancer	100.07	11.99	76.57	123.57	p = 0.201
C-MYC Amplification
< 2	93.96	8.96	76.41	111.52
> 2	117.03	9.98	97.47	136.59	p = 0.265